Home » Posts tagged 'anax labs' (Page 8)
Tag Archives: anax labs
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....FOR BLOG HOME CLICK HEREFlag and hits
ORGANIC SPECTROSCOPY
SUBSCRIBE
Subscribe in a reader
Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by Email
Recent Comments
 | shivkr2 on SPSR Excellence Award 2025 – S… |
 | Bonkasaurus on Infigratinib phosphate |
 | PALOVAROTENE | ORGAN… on Palovarotene |
| Pfizer just purchase… on Temanogrel | |
| Pfizer To Cash In On… on Temanogrel |
Elsovaptan
Elsovaptan
CAS 2296801-25-5
MFC19H20ClN5O2 MW385.8 g/mol
[(3S)-7-chloro-3-methyl-2,3-dihydro-1,4-benzoxazin-4-yl]-(6-pyrimidin-2-yl-2,6-diazaspiro[3.3]heptan-2-yl)methanone
[(3S)-7-chloro-3-methyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl][6-(pyrimidin-2-yl)-2,6-diazaspiro[3.3]heptan-2-yl]methanone
vasopressin receptor antagonist, Alzheimer disease, T206306, Y2Z74WGU3J
Elsovaptan is a selective vasopressin receptor antagonist. It is primarily used in scientific research to study the modulation of vasopressin action, particularly in the context of neurodegenerative conditions like Alzheimer’s disease
- Primary Mechanism: Blocks the binding of vasopressin to its receptors, which typically disrupts fluid volume regulation and can lead to vasodilation.
Research Applications
Currently, Elsovaptan is designated as a research-use-only compound and is not approved for human therapeutic or veterinary use.
Its study is often linked to research on:
- Neurodegenerative Diseases: Investigating the role of the vasopressin system in the progression of Alzheimer’s disease.
- Fluid Regulation: Understanding how antagonizing vasopressin affects vascular resistance and blood pressure.
The compound has been listed in recent International Nonproprietary Names (INN) proposals by the World Health Organization (WHO) for pharmaceutical substances, indicating it is an active subject of pharmacological study
ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect
Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
References
/////////elsovaptan, ANAX LABS, vasopressin receptor antagonist, Alzheimer disease, T206306, Y2Z74WGU3J
Elisrasib
Elisrasib
CAS2914919-85-8
MFC32H35F6N7O3. MW 679.7 g/mol
2-[(2S)-4-[(7S)-7-[3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl]-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile
[(2S)-4-[(7S)-7-[3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl]-2-{[(2R,7aS)-2-fluorotetrahydro-1Hpyrrolizin-7a(5H)-yl]methoxy}-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile
Kirsten rat sarcoma viral oncogene homolog inhibitor, antineoplastic, D3S 001, PFW9YLB86H
Elisrasib (D3S-001) is a next-generation, orally available KRAS G12C inhibitor developed by D3 Bio that demonstrates high potency, sustained target engagement, and strong clinical activity in advanced solid tumors, including those resistant to first-generation inhibitors. As of April 2026, clinical trials show it has a 52% objective response rate (ORR) in G12C inhibitor-naive patients and a 30% ORR in refractory populations.
Key Aspects of Elisrasib (D3S-001):
- Mechanism of Action: It is a highly potent, covalent inhibitor that selectively binds the GDP-bound (inactive) form of the KRAS G12C mutant, effectively halting tumor cell proliferation and metastasis.
- Superior Efficacy: Preliminary data suggests elisrasib may be more potent than earlier inhibitors like sotorasib and adagrasib, providing higher target occupancy at lower doses.
- Clinical Performance (AACR 2026 Data):
- Naive Patients: 52% ORR, with a median duration of response (mDOR) of 16.5 months and median progression-free survival (mPFS) of 12.2 months at the 600 mg dose.
- Refractory Patients: 32% ORR, with a mDOR of 15.6 months and mPFS of 8.1 months.
- Targeted Cancers: Clinical trials are focused on KRAS G12C-mutant tumors, specifically non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors.
- Safety Profile: The drug has shown good tolerability and a safe profile in early studies.
Elisrasib is in Phase 1/2 development and was highlighted for its promising results in treating patients with KRAS G12C-mutant tumors
Elisrasib is an orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C, with potential antineoplastic activity. Upon oral administration, elisrasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C-mediated signaling. This may halt proliferation and metastasis in susceptible tumor cells. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis.
- A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult ParticipantsCTID: NCT07093398Phase: Phase 1Status: CompletedDate: 2026-03-25
- A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway MutationsCTID: NCT05886920Phase: Phase 1/Phase 2Status: Active, not recruitingDate: 2026-03-23
- A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C MutationCTID: NCT05410145Phase: Phase 1/Phase 2Status: RecruitingDate: 2026-03-12
PAT
SYN
Example 17
Step 6: Synthesis of Compound 17
ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect
Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
References
- Pyrimidoheterocyclic compounds and application thereofPublication Number: EP-4105211-A1Priority Date: 2020-03-12
- Pyrimidoheterocyclic compounds and application thereofPublication Number: US-2023151004-A1Priority Date: 2020-03-12
//////////elisrasib, anax labs, Kirsten rat sarcoma viral oncogene homolog inhibitor, antineoplastic, D3S 001, PFW9YLB86H
Elironrasib
Elironrasib
CAS 2641998-63-0
MFC55H78FN9O8 MW 1012.3 g/mol
1-[4-(dimethylamino)-4-methylpent-2-ynoyl]-N-[(2S)-1-[[(6S,8S,14S)-22-ethyl-21-[2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]amino]-3-methyl-1-oxobutan-2-yl]-4-fluoro-N-methylpiperidine-4-carboxamide
- 1-[4-(dimethylamino)-4-methylpent-2-ynoyl]-N-[(2S)-1-[[(6S,8S,14S)-22-ethyl-21-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]amino]-3-methyl-1-oxobutan-2-yl]-4-fluoro-N-methylpiperidine-4-carboxamide
- 3-Pyridazinecarboxylic acid, N1-[N-[[1-[4-(dimethylamino)-4-methyl-1-oxo-2-pentyn-1-yl]-4-fluoro-4-piperidinyl]carbonyl]-N-methyl-L-valyl-3-[4-[(2R)-1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-[2-[(1S)-1-methoxyethyl]-3-pyridinyl]-1H-indol-5-yl]-2-morpholinyl]-L-alanyl]hexahydro-, (3–>2)-lactone, (3S)-
Kirsten rat sarcoma viral oncogene homolog inhibitor, antineoplastic, RMC-6291, RMC 6291, 942KVV5CJP
Elironrasib (RMC-6291) is an investigational, orally bioavailable, RAS(ON) G12C-selective inhibitor developed by Revolution Medicines that targets the active GTP-bound form of KRAS G12C. In Phase 1 trials, it showed significant promise in treating advanced KRAS G12C-mutated solid tumors, including non-small cell lung cancer (NSCLC). [1, 2, 3]
Key Clinical Trial Results (as of Oct 2025):
- Response Rate: 42% objective response rate (ORR).
- Disease Control: 79% disease control rate (DCR).
- Durability: Median duration of response was 11.2 months.
- Survival: Median progression-free survival was 6.2 months.
- Overcoming Resistance: Demonstrated efficacy in patients who had previously progressed on first-generation KRAS G12C(OFF) inhibitors.
Mechanism of Action:
Elironrasib acts as a covalent tri-complex inhibitor (TCI). It forms a complex with the intracellular chaperone protein cyclophilin A (CypA) and the active KRAS G12C(GTP) protein, effectively shutting down oncogenic signaling.
Development Status:
- Designation: It has received FDA breakthrough therapy designation for KRAS G12C-mutant NSCLC.
- Trials: Currently in Phase 1 clinical trials (e.g., NCT05462717) to evaluate safety, tolerability, and efficacy, both as a monotherapy and in combination.
- Target Population: Patients with KRAS G12C-addicted solid tumors.
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers – PubMed27 Mar 2025 — This information does not constitute medical advice or diagnosis. Elirronrasib (RMC-6291) is a potent, orally bioavailable,
- Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor22 Oct 2025 — This information does not constitute medical advice or diagnosis. Elirronrasib is a RAS(ON) G12C-selective inhibitor being develop…
Revolution Medicines
- Elironrasib May Overcome Resistance to Prior KRAS G12C Inhibition in Non-small Cell Lung Cancer
- OriginatorREVOLUTION Medicines
- ClassAntineoplastics; Morpholines; Piperidines; Pyridazines; Small molecules
- Mechanism of ActionKRAS protein inhibitors
- Phase I/IISolid tumours
- Clinical Phase UnknownNon-small cell lung cancer
- 30 Jan 2026Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT07397338)
- 31 Oct 2025Elironrasib is still in phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in Australia, Italy, South Korea, Malaysia, Singapore, Spain, Czech Republic, Thailand and USA (PO, Tablet) (NCT05462717)
- 28 Oct 2025No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy) in Australia, Italy, South Korea, Malaysia, Singapore, Spain, Czech Republic, Thailand (PO, Tablet)
Elironrasib is an orally bioavailable, covalent inhibitor of the active, guanosine triphosphate (GTP)-bound form of the oncogenic KRAS substitution mutation G12C, KRAS G12C(ON), with potential antineoplastic activity. Upon oral administration, elironrasib forms a tri-complex with the intracellular chaperone protein and immunophilin cyclophilin A (CypA) and KRAS G12C(ON). This tri-complex inhibits KRAS G12C(ON)-mediated signaling, which may inhibit tumor cell proliferation. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsCTID: NCT06128551Phase: Phase 1/Phase 2Status: RecruitingDate: 2026-04-23
- Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsCTID: NCT05462717Phase: Phase 1Status: Active, not recruitingDate: 2026-04-08
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsCTID: NCT07397338Phase: Phase 1/Phase 2Status: RecruitingDate: 2026-03-30
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCCTID: NCT06162221Phase: Phase 1/Phase 2Status: RecruitingDate: 2026-03-09
SYN
https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02313
SYN
PAT’
Part 5—Synthesis of Compound A—(12M)-1-(4-(dimethylamino)-4-methylpent-2 ynoyl)-N-((2S)-1-(((22S,63S,4S)-11-ethyl-12-(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-61,62,63,64,65,66-hexahydro-11H-8-oxa-2(4,2)-morpholina-1(5,3)-indola-6(1,3) pyridazinacycloundecaphane-4-yl)amino)-3-methyl-1-oxobutan-2 yl)-4-fluoro-N-methylpiperidine-4-carboxamide
| To a 50 L glass reactor was charged Compound 15 (1.91 kg, 1.0 eq) and DMF (13.9 kg). The mixture was agitated at 20-30° C. until all of the solids were dissolved. Compound 2 (1.70 kg, 1.2 eq) and DMF (3.8 kg) were charged. The mixture was agitated at 20-30° C. until all of the solids were dissolved. DIPEA (2.20 kg, 5.50 eq) was charged at 20-30° C. and the mixture was cooled to −20-−10° C. under agitation. Ethyl cyanoglyoxylate-2-oxime (Oxyma) (0.48 kg, 1.1 eq) was charged to the reactor and the reaction mixture was agitated at −20 to −10° C. for 30 min. PyBOP was charged as a DMF solution (1.89 kg dissolved in 3.62 kg DMF, 1.2 eq) to the reactor at −20 to −10° C. in </=1 h. The reaction mixture was agitated at −20 to −10° C. for 1-3 h. Reaction monitoring by HPLC showed the reaction was complete. |
| The crude product was then further purified by recrystallization with a mixture of EtOAc and n-Heptane to give purified Compound A as a white solid. |
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect
Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma
References
- Macrocyclic heterocycles and uses thereofPublication Number: US-2023339952-A1Priority Date: 2022-04-20
- Macrocyclic heterocycles and uses thereofPublication Number: WO-2023205701-A1Priority Date: 2022-04-20
- Methods for delaying, preventing, and treating acquired resistance to ras inhibitorsPublication Number: US-2023233569-A1Priority Date: 2020-06-18
- Ras inhibitorsPublication Number: US-2021130303-A1Priority Date: 2019-11-04
- Ras inhibitorsPublication Number: US-2023234929-A1Priority Date: 2019-11-04
- Ras inhibitors
- Publication Number: US-11566007-B2
- Priority Date: 2019-11-04
- Grant Date: 2023-01-31
////////elironrasib, ANAX LABS, Kirsten rat sarcoma viral oncogene homolog inhibitor, antineoplastic, RMC-6291, RMC 6291, 942KVV5CJP
Elecoglipron
Elecoglipron
CAS 3011682-49-5
MFC48H46F2N10O5 MW880.9 g/mol
3-[1-[2-[(4S)-2-(3-cyclopropyl-4-fluorophenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-7-[(4S)-2,2-dimethyloxan-4-yl]indolizin-3-yl]cyclopropyl]-4H-1,2,4-oxadiazol-5-one
- 1,2,4-Oxadiazol-5(2H)-one, 3-[1-[2-[[(4S)-2-(3-cyclopropyl-4-fluorophenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-7-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-3-indolizinyl]cyclopropyl]-
- 3-(1-(2-((S)-2-(3-cyclopropyl-4-fluorophenyl)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-7-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)indolizin-3-yl)cyclopropyl)-1,2,4-oxadiazol-5(4H)-one
- 3-[1-[2-[(4S)-2-(3-cyclopropyl-4-fluorophenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-7-[(4S)-2,2-dimethyloxan-4-yl]indolizin-3-yl]cyclopropyl]-4H-1,2,4-oxadiazol-5-one
glucagon-like peptide 1 (GLP-1) receptor agonist, AZD 5004, ECC 5004, G94JJ74N5Y
Elecoglipron (AZD5004 / ECC-5004) is a glucagon-like peptide 1 (GLP-1) receptor agonist. In vitro, AZD5004/ECC5004 binds the human GLP-1 receptor with high affinity (IC₅₀ ~ 2.4 nM), drives G s-coupled cAMP signaling with low-nanomolar potency (EC₅₀ ~ 2–6 nM in HEK293/β-cell cAMP and GSIS assays), shows partial agonism in some cell systems without detectable β-arrestin recruitment or receptor internalization, and potentiates glucose-stimulated insulin secretion (EC₅₀ ~ 5.9 nM). In in vivo non-human primate studies, oral dosing produced robust pharmacodynamic effects — insulin secretion and glucose clearance with estimated EC₅₀ ~ 0.022 nM — and dose-dependent reductions in body-weight gain over long-term dosing, consistent with GLP-1-mediated metabolic effects
PAT
US-11584751-B1
https://patentscope.wipo.int/search/en/detail.jsf?docId=US392022131&_cid=P22-MOWB0S-70559-1
PAT
US-12037339-B2
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
References
- Substituted imidazoles as GLP-1 receptor agonistsPublication Number: US-12037339-B2Priority Date: 2020-07-20Grant Date: 2024-07-16
- Substituted imidazoles as GLP-1 receptor agonistsPublication Number: US-11584751-B1Priority Date: 2020-07-20Grant Date: 2023-02-21
//////elecoglipron, anax labs, glucagon-like peptide 1 (GLP-1) receptor agonist, AZD 5004, ECC 5004, G94JJ74N5Y
Egalognastat
Egalognastat
CAS 1884154-02-2
MF C17H21N5O3S MW375.45
(S)-N-(5-(4-(1-(BENZO(D)(1,3)DIOXOL-5-YL)ETHYL)PIPERAZIN-1-YL)-1,3,4-THIA-DIAZOL-2-YL)ACETAMIDE
ACETAMIDE, N-(5-(4-((1S)-1-(1,3-BENZODIOXOL-5-YL)ETHYL)-1-PIPERAZINYL)-1,3,4-THIADIAZOL-2-YL)-
N-(5-{4-[(1S)-1-(2H-1,3-benzodioxol-5-yl)ethyl]piperazin-1-yl}-1,3,4-thiadiazol-2-yl)acetamide
O-GlcNAcase enzyme inhibitor, ASN90, ASN 90, E9QIS63WUM, ASN 120290
Egalognastat (ASN90) is a potent, selective, and brain-penetrant O-GlcNAcase (OGA) inhibitor (\(IC_{50} = 10.2 \text{ nM}\)). It acts as a disease-modifying agent in pre-clinical studies for neurodegenerative conditions by enhancing protein O-GlcNAcylation, which regulates tau and \(\alpha \)-synuclein pathology. Egalognastat is under investigation for diseases like Alzheimer’s and Parkinson’s.
Key Details on Egalognastat (ASN90):
- Mechanism: As a substrate-competitive OGA inhibitor, it binds to the OGA enzyme and reduces the removal of O-GlcNAc from proteins.
- Disease Targets: It is primarily studied for tauopathies and \(\alpha \)-synucleinopathies.
- Efficacy: Preclinical data shows it raises O-GlcNAcylation of brain proteins and has shown therapeutic potential in models of neurodegeneration.
- Distinction: Unlike earlier sugar-based inhibitors (like Thiamet G), Egalognastat is chemically distinct.
- Status: It is primarily used for research and preclinical development.
- Related Research: Recent studies (2025) have analyzed the potential synaptotoxic effects of OGA inhibitors, including Egalognastat (ASN90) and Ceperognastat, indicating that while they are effective for removing misfolded proteins, they may interfere with synaptic plasticity.
SYN
Publication Name: Journal of Medicinal Chemistry
Publication Date: 2024-08-07
PMID: 39109492
DOI: 10.1021/acs.jmedchem.4c01132
SYN
PAT
PAT
PAT
- Glycosidase inhibitorsPublication Number: US-12187741-B2Priority Date: 2014-08-28Grant Date: 2025-01-07
- Glucosidase inhibitorsPublication Number: ES-2893289-T3Priority Date: 2014-08-28Grant Date: 2022-02-08
- Glycosidase inhibitorsPublication Number: EP-3186243-B1Priority Date: 2014-08-28Grant Date: 2021-07-21
- Glycosidase inhibitorsPublication Number: US-10336775-B2Priority Date: 2014-08-28Grant Date: 2019-07-02
- Glycosidase inhibitorsPublication Number: US-11046712-B2Priority Date: 2014-08-28Grant Date: 2021-06-29
- Glycosidase inhibitorsPublication Number: EP-3868752-A1Priority Date: 2014-08-28
- Glycosidase InhibitorsPublication Number: CN-107108601-APriority Date: 2014-08-28
- Glycosidase inhibitorsPublication Number: US-2019367533-A1Priority Date: 2014-08-28
- Glycosidase inhibitorsPublication Number: WO-2016030443-A1Priority Date: 2014-08-28
- Glycosidase inhibitorsPublication Number: EP-3186243-A1Priority Date: 2014-08-28
- Glycosidase inhibitorPublication Number: JP-2019206554-APriority Date: 2014-08-28
- Glycosidase inhibitorsPublication Number: US-2017298082-A1Priority Date: 2014-08-28
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
References
////////egalognastat, anax labs, O-GlcNAcase enzyme inhibitor, ASN90, ASN 90, E9QIS63WUM, ASN 120290
Dirozalkib
Dirozalkib
CAS 1893419-37-8
MF C27H32ClN5O4S MW558.1 g/mol
5-chloro-2-N-(6-methyl-5-piperidin-4-yl-2,3-dihydro-1,4-benzodioxin-8-yl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
anaplastic lymphoma kinase (ALK) inhibitor, antineoplastic, XZP-3621, XZP 3621, Xuanzhu Biopharmaceutical, 2FH56C28YT
Dirozalkib (XZP-3621) is a novel, potent, and highly selective ALK/ROS1 tyrosine kinase inhibitor developed by Xuanzhu Biopharmaceutical to treat advanced ALK-positive non-small cell lung cancer (NSCLC). It demonstrated high efficacy (47.4% ORR, up to 89.3% in naive patients) in clinical trials and is designed to overcome resistance to earlier inhibitors.
Key Aspects of Dirozalkib
- Indication: Treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Mechanism: Acts as a dual-target ALK/ROS1 tyrosine kinase inhibitor (TKI), effective against ALK fusion-positive cells and various resistance mutations.
- Clinical Efficacy (Phase I/II): In studies, the drug showed significant antitumor activity with an Objective Response Rate (ORR) of 47.4% and an 89.3% ORR in ALK inhibitor-naive patients at 500 mg/day.
- Safety Profile: No dose-limiting toxicities occurred; the maximum tolerated dose was 600 mg/day, with a recommended dose of 500 mg/day. Common adverse events included diarrhea.
- Status: As of early 2026, the NDA (New Drug Application) for Dexitinib (Dirozalkib) was accepted by China’s NMPA, with potential for further market expansion.
- OriginatorXuanzhu Biopharmaceutical
- Class2 ring heterocyclic compounds; Amines; Aniline compounds; Antineoplastics; Chlorinated hydrocarbons; Piperidines; Pyrimidines; Small molecules; Sulfones
- Mechanism of ActionAnaplastic lymphoma kinase inhibitors
- RegisteredNon-small cell lung cancer
- 26 Aug 2025Chemical structure information added.
- 22 Aug 2025Registered for Non-small cell lung cancer (Late-stage disease) in China (PO) – First global approval
- 22 Aug 2025Efficacy and adverse events data from a phase III trial in Non-small cell lung cancer released by Xuanzhu Biopharmaceutical
- A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung CancerCTID: NCT05055232Phase: Phase 1Status: CompletedDate: 2025-07-24
- Food Effect and Mass Balance Study of XZP-3621 TabletsCTID: NCT05034120Phase: Phase 1Status: CompletedDate: 2025-05-25
- A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLCCTID: NCT05482087Phase: Phase 2Status: Unknown statusDate: 2022-08-01
- A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus CrizotinibCTID: NCT05204628Phase: Phase 3Status: Unknown statusDate: 2022-01-24
PAT
PAT
Example 3 Preparation of 2-((5-chloro-2-((7-methyl-8-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin- 5-yl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide (compound 3)
(5) Preparation of 2-((5-chloro-2-((7-methyl-8-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide
75 mg (0.114 mmol) of tert-butyl 4-(8-((5-chloro-4-((2-(N,N-dimethylaminosulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-6-methyl-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine-1-carboxylic acid ester was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (1 mL) was added. The mixture was stirred at room temperature for 12 hours. The starting material disappeared as detected by TLC. Water (20 mL) was added, and the mixture was separated. The aqueous phase was extracted twice with dichloromethane (20 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation. The crude product was purified by silica gel column chromatography (methanol:dichloromethane = 1:50) to obtain the final product (30 mg, yield 47.2%).
[0415]Molecular formula:
C26H31ClN6O4S Molecular weight: 559.08 LC-MS (m / z): 280.2 [ M /2+H ] +
[0416]
1H-NMR(400MHz,MeOD)δ:8.44(d,1H,J＝1.2),8.11(s,1H),7.86(d,1H,J＝1.2),7.56-7.60(m,1H),7.28-7.35(m,2H),4.26(s,4H),3.45-3.48(m,2H),3.06-3.15(m,3H),2.56-2.74(m,8H),2.17(s,3H),1.76-1.80(m,2H).
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
References
- Polycyclic inhibitor of anaplastic lymphoma kinasePublication Number: US-10011592-B2Priority Date: 2014-09-29Grant Date: 2018-07-03
- Polycyclic inhibitor of anaplastic lymphoma kinasePublication Number: US-2018086745-A9Priority Date: 2014-09-29
- Polycyclic anaplastic lymphoma kinase inhibitorPublication Number: EP-3202765-A1Priority Date: 2014-09-29
- Polycyclic inhibitor of anaplastic lymphoma kinasePublication Number: KR-20170055555-APriority Date: 2014-09-29
- Crystal form of polycyclic anaplastic lymphoma kinase inhibitorPublication Number: US-2023348443-A1Priority Date: 2020-01-17
- Crystal form of polycyclic anaplastic lymphoma kinase inhibitorPublication Number: US-12441717-B2Priority Date: 2020-01-17Grant Date: 2025-10-14
- Polycyclic inhibitor of anaplastic lymphoma kinasePublication Number: US-2017240534-A1Priority Date: 2014-09-29
- Polycyclic inhibitor of anaplastic lymphoma kinasePublication Number: KR-101909404-B1Priority Date: 2014-09-29Grant Date: 2018-10-17
- Polycyclic anaplastic lymphoma kinase inhibitorPublication Number: WO-2016050171-A1Priority Date: 2014-09-29
- Pharmaceutical composition of anaplastic lymphoma kinase inhibitor and preparation method thereforPublication Number: WO-2025140560-A1Priority Date: 2023-12-28
- CRYSTALLINE FORM OF A POLYCYCLIC ANAPLASIC LYMPHOMA KINASE INHIBITORPublication Number: EP-4092021-A4Priority Date: 2020-01-17
- Polycyclic anaplastic lymphoma kinase inhibitor crystalline formPublication Number: CN-113135905-BPriority Date: 2020-01-17Grant Date: 2023-11-21
- Crystal form of polycyclic anaplastic lymphoma kinase inhibitorPublication Number: WO-2021143819-A1Priority Date: 2020-01-17
- Crystal form of polycyclic anaplastic lymphoma kinase inhibitorPublication Number: EP-4092021-A1Priority Date: 2020-01-17
/////////dirozalkib, anax labs, anaplastic lymphoma kinase (ALK) inhibitor, antineoplastic, XZP-3621, XZP 3621, Xuanzhu Biopharmaceutical, 2FH56C28YT
Deulumateperone
Deulumateperone
CAS 2102683-75-8
MF C24H262H2FN3O MW 395.5 g/mol
4-[(10R,15S)-3,3-dideuterio-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]-1-(4-fluorophenyl)butan-1-one
- 1-(4-Fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-2-d-3-methyl-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl-2-d]-1-butanone
- 1-Butanone, 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-2-d-3-methyl-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl-2-d]-
antipsychotic, ITI-1284, ITI 1284, NBA7J58PPP,
Deulumateperone (INNTooltip International Nonproprietary Name; developmental code name ITI-1284) is an experimental antipsychotic of the pyridopyrroloquinoxaline and butyrophenone families as well as a deuterated analogue of lumateperone which is under development as a sublingually administered orally disintegrating tablet (ODT) for the treatment of psychotic disorders, agitation, and generalized anxiety disorder.[2][3][4][1] No recent development has been reported for treatment of depressive disorders, behavioral disorders, and dementia.[2] It is being developed by Intra-Cellular Therapies.[2][3][1] As of January 2025, it has reached phase 2 clinical trials.[2][3]
SYN
PAT
Example 2
2,2-D2-1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3′,4′: 4,5]pyrrolo[1,2,3-de]quinoxalin-8(9H)-yl)butan-1-one
| To a suspension of (6bR, 10aS)-3-Methyl-2-oxo-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′: 4,5]pyrrolo[1,2,3-de]quinoxaline-8-carboxylic acid ethyl ester (945 mg, 3 mmol) in THF (5 mL) is slowly added BD 3-THF (1.0 M in THF, 10 mL, 10 mmol) at room temperature. After completion of the addition, the reaction mixture is stirred at room temperature overnight and then carefully quenched with D 2O (2.0 mL). The solvent is removed under vacuum and the residue is suspended in HCl (12 N, 9 mL). After stirred at 95° C. for 20 h, the reaction mixture is cooled to room temperature and then adjusted to pH of 12 with 50% NaOH. The mixture is concentrated to dryness to give 2,2-d 2-(6bR, 10aS)-3-Methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3′,4′: 4,5]pyrrolo[1, 2,3-de]quinoxaline as a brown solid, which is used directly for next step without further purification. MS (ESI) m/z 232.2 [M+H] +. |
PAT
- Novel compositions and methodsPublication Number: US-2021315891-A1Priority Date: 2018-08-29
- Transmucosal and subcutaneous compositionsPublication Number: US-10716786-B2Priority Date: 2017-03-24Grant Date: 2020-07-21
- Novel compositions and methodsPublication Number: US-2018271862-A1Priority Date: 2017-03-24
- Transmucosal methods for treating psychiatric and neurological conditionsPublication Number: US-11052083-B2Priority Date: 2017-03-24Grant Date: 2021-07-06
- Novel compositions and methodsPublication Number: US-2020375988-A1Priority Date: 2017-03-24
- Novel compositions and methodsPublication Number: US-2021361648-A1Priority Date: 2017-03-24
- Organic compoundsPublication Number: US-2019231780-A1Priority Date: 2016-03-25
- Organic compoundsPublication Number: US-10688097-B2Priority Date: 2016-03-25Grant Date: 2020-06-23
- Organic compoundsPublication Number: US-11096944-B2Priority Date: 2016-03-25Grant Date: 2021-08-24
- Organic compoundsPublication Number: US-2020352949-A1Priority Date: 2016-03-25
- Organic compounds
- Publication Number: US-2022008423-A1
- Priority Date: 2016-03-25
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
References
References
- Oguma T, Jino K (2024). “Clinical Pipelines for Alzheimer’s Disease Psychosis and Agitation”. Chemical & Pharmaceutical Bulletin. 72 (7) c23-00416: 610–617. doi:10.1248/cpb.c23-00416. PMID 38945937.
- “Intra-Cellular Therapies”. AdisInsight. 29 January 2025. Retrieved 26 February 2025.
- “Delving into the Latest Updates on ITI-1284 with Synapse”. Synapse. 20 February 2025. Retrieved 26 February 2025.
- “Proposed INN: List 132 International Nonproprietary Names for Pharmaceutical Substances (INN)” (PDF). WHO Drug Information. 38 (4): 1073. 2024.
| Clinical data | |
|---|---|
| Other names | Lumateperone deuterated; Deuterated lumateperone; ITI-1284; ITI1284; ITI-1284-ODT-SL |
| Routes of administration | Sublingual (orally disintegrating tablet)[1] |
| Drug class | Atypical antipsychotic |
| Identifiers | |
| IUPAC name | |
| CAS Number | 2102683-75-8 |
| PubChem CID | 140916642 |
| UNII | NBA7J58PPP |
| KEGG | D13268 |
| Chemical and physical data | |
| Formula | C24H26D2FN3O |
| Molar mass | 395.518 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES | |
| InChI | |
////////deulumateperone, anax labs, antipsychotic, ITI-1284, ITI 1284, NBA7J58PPP,
Daraxonrasib
Daraxonrasib
CAS 2765081-21-6
8/26/2026, FDA APPROVED 2026, FDA 2026, Rasonque
MFC44H58N8O5S MW811.0 g/mol
trans-(1S,2S)-N-[(7S,13S)-21-ethyl-20-[2-[(1S)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)-3-pyridinyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.12,5.19,13.022,26]octacosa-1(25),2,5(28),19,22(26),23-hexaen-7-yl]-2-methylcyclopropane-1-carboxamide
Kirsten rat sarcoma viral oncogene homolog inhibitor, antineoplastic, RMC-6236, RMC 6236, B6T47Y2UAP, RAS-IN-2,
To treat metastatic pancreatic cancer
Daraxonrasib (formerly RMC-6236) is an investigational, orally administered “molecular glue” RAS inhibitor developed by Revolution Medicines for treating advanced solid tumors with RAS mutations, particularly metastatic pancreatic cancer. April 2026 Phase 3 trials showed it significantly improves survival, demonstrating high potential as a first-line treatment.
Key Clinical Findings and Updates (as of April 2026):
- Mechanism: It acts as a RAS(ON) inhibitor, targeting mutated and wild-type RAS proteins (
) to disrupt cancer signaling.
- Breakthrough Results: Data from the RASolute 302 trial showed a substantial survival benefit in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
- High Response Rates: In trials, daraxonrasib combined with chemotherapy showed a 58% confirmed objective response rate (ORR) and 84% progression-free survival (PFS) at 6 months in untreated RAS-mutant metastatic pancreatic cancer.
- Safety Profile: Generally well-tolerated, with side effects including rash, diarrhea, stomatitis, and nausea.
- Recognition: Named the “2025 Molecule of the Year” by Drug Hunter for its, novel mechanism and clinical potential.
Daraxonrasib is currently being studied in the Phase 3 RASolute 303 trial for first-line treatment of pancreatic cancer.
Daraxonrasib (RMC-6236) is a RAS inhibitor drug. It is undergoing testing by Revolution Medicines to treat advanced solid tumors with RAS mutations, especially metastatic pancreatic ductal adenocarcinoma (PDAC) containing KRAS G12X mutations.[1] It received a breakthrough therapy designation from the U.S. Food and Drug Administration.[2]
Daraxonrasib is orally active and multi-selective RAS inhibitor. It uses a tri-complex mechanism to target the active, GTP-bound form of RAS proteins, including mutant and wild-type forms. Unlike conventional RAS inhibitors, it first binds to the chaperone-like protein cyclophilin A to form a complex, which then attaches to active RAS. This interaction blocks downstream effector binding and inhibits oncogenic signaling.[3]
In 2026, Daraxonrasib clinical trial completed a phase 3 clinical trial (RASolute 302) to assess efficacy compared to standard-of-care chemotherapy.[4] The trial met all primary and key secondary endpoints, including progression-free survival (PFS). The company reported median survival of 13.2 months with daraxonrasib vs. 6.7 months with standard chemotherapy. The hazard ratio for death was 0.40 (a 60% reduction in risk of death; p < 0.0001). Daraxonrasib was generally well tolerated with a manageable safety profile and no new safety signals.[5]
PAT
PAT
PATENT ATTORNEY DOCKET: 51432-038WO2 Part 4 – Purification of Compound A – (1S,2S)-N-[(7S,13S)-21-ethyl-20-{2-[(1S)-1- methoxyethyl]-5-(4-
1.0equiv) at 25°C. The resulting suspension was stirred until solids were completely dissolved. The resulting methanol solution was filtered through microporous filter and transferred to another reactor. Then the reactor temperature was maintained at 25°C and slowly water (2.41kg, 1.0 V) water was added over a period of 30 minutes. The resulting cloudy solution was stirred for another 30 minutes at 25°C. Then a solution of methanol and water (3.42kg, 1:2, v/v) slowly over 1 hour. The resulting suspension was stirred for 2 hours at 25°C. Again, to the suspension additional water (2.48kg) slowly added over 1 hour. The final, suspension was stirred for additional 1 hour. Water (9.29kg, 3.75 V) was added to the suspension slowly over 2 hours and the mixture was stirred for at least for 16 hours at 25°C. The resulting suspension was filtered and washed with mixed solvent water: MeOH (3:2, v/v) twice (2x 2.2 kg), followed by water (4.91kg) washing. The wet cake was dried under reduced pressure and controlled humidity (temperature: 25 ± 5 ˚C, vacuum ≥ -0.085 MPa, humidity: 10%~20%) for 37 hours to afford Compound A as a white solid (2.68 kg, 99.4% a/a purity, 93.0% w/w assay, KF: 6.7%, 3.07 mol, 92% yield, Table 27).
PAT
- Synthesis of ras inhibitorsPublication Number: WO-2024216017-A2Priority Date: 2023-04-14
- Macrocycle compounds useful as kras inhibitorsPublication Number: WO-2024008834-A1Priority Date: 2022-07-08
- Ras inhibitorsPublication Number: US-11690915-B2Priority Date: 2020-09-15Grant Date: 2023-07-04
- Ras inhibitorsPublication Number: US-2023226186-A1Priority Date: 2020-09-15
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
References
References
- Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson AC, et al. (March 2025). “Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers”. Journal of Medicinal Chemistry. 68 (6): 6064–6083. doi:10.1021/acs.jmedchem.4c02314. PMID 40056080.
- Sava J (July 1, 2025). “Daraxonrasib Earns FDA Breakthrough Status in Pancreatic Cancer”. Targeted Oncology. Retrieved October 12, 2025.
- Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. (June 2024). “Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers”. Cancer Discovery. 14 (6): 994–1017. doi:10.1158/2159-8290.CD-24-0027. PMC 11149917. PMID 38593348.
- Clinical trial number NCT05379985 at ClinicalTrials.gov
- Mast J (2026-04-13). “Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill”. STAT. Retrieved 2026-04-13.
| Clinical data | |
|---|---|
| Other names | RMC-6236 |
| Identifiers | |
| IUPAC name | |
| CAS Number | 2765081-21-6 |
| PubChem CID | 164726578 |
| IUPHAR/BPS | 13368 |
| ChemSpider | 115275938 |
| UNII | B6T47Y2UAP |
| KEGG | D13265 |
| ChEBI | CHEBI:746946 |
| Chemical and physical data | |
| Formula | C44H58N8O5S |
| Molar mass | 811.06 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES | |
| InChI | |
//////////daraxonrasib, anax labs, Kirsten rat sarcoma viral oncogene homolog inhibitor, antineoplastic, RMC-6236, RMC 6236, B6T47Y2UAP, RAS-IN-2, FDA APPROVED 2026, FDA 2026, Rasonque
#daraxonrasib, #anax labs, #Kirsten rat sarcoma viral oncogene homolog inhibitor, #antineoplastic, #RMC-6236, #RMC 6236, B6T47Y2UAP, #RAS-IN-2, #APPROVALS 2026, #FDA 2026, #Rasonque
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect
Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma
New Drug Approvals 
